Endometrial carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant tumor arising from the epithelium that lines the cavity of the uterine body. The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases. Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma. Uterine bleeding is an initial clinical sign. The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Endometrial carcinoma
- Therapeutic area
- Oncology
- endometrial carcinoma
- endometrial cancer
- carcinoma of endometrium
- carcinoma of the endometrium
- carcinoma, endometrial, malignant
- endometrial carcinoma
- endometrial carcinoma (disease)
- endometrium carcinoma
- Severity
- Severe
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0002447
- Parent condition
- MONDO:0005213
Related records
Broader conditions (23)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endometrial cancer
- Endometrial disorder
- Endometrium neoplasm
- Epithelial neoplasm
- Female reproductive organ cancer
- Female reproductive system disorder
- Female reproductive system neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Reproductive system cancer
- Reproductive system disorder
- Reproductive system neoplasm
- Tumor of uterus
Narrower conditions (18)
- Endometrial adenosquamous carcinoma
- Endometrial clear cell adenocarcinoma
- Endometrial endometrioid adenocarcinoma with spindled epithelial cells
- Endometrial mixed adenocarcinoma
- Endometrial mucinous adenocarcinoma
- Endometrial small cell carcinoma
- Endometrial squamous cell carcinoma
- Endometrial transitional cell carcinoma
- Endometrial undifferentiated carcinoma
- Endometrium adenocarcinoma
- Endometrium carcinoma in situ
- Mucin-rich endometrial endometrioid adenocarcinoma
- Ovarian endometrioid adenocarcinoma
- Ovarian endometrioid adenocarcinoma with squamous differentiation
- Oxyphilic endometrial endometrioid adenocarcinoma
- Secretory uterine corpus endometrioid adenocarcinoma
- Uterine corpus endometrial carcinoma
- Villoglandular endometrial endometrioid adenocarcinoma
Trials (173)
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- A Beta-only IL-2 ImmunoTherapY Study
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
- A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
- A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
- A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
- A Prospective Multi-center Study on Using Sonazoid Diagnose Early Stage Endometrial Cancer
- A Study Evaluating MM-310 in Patients With Solid Tumors
- A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
- A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
- A Study of Nivolumab in Selected Uterine Cancer Patients
- A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma
- A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
- A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility
- A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
- A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
Approved drugs (1)
Drugs in development (48)
- Aflibercept Phase 2
- Anastrozole Phase 1
- Apitolisib Phase 2
- Arsenic trioxide Phase 2
- Bevacizumab Phase 2
- Camrelizumab Phase 2
- Carboplatin Phase 3
- Catequentinib Phase 2
- Cisplatin Phase 3
- Cridanimod Phase 2
- Docetaxel Phase 3
- Doxorubicin Phase 3
- Durvalumab Phase 3
- Edodekin alfa Phase 1
- Epacadostat Phase 2
- Fluzoparib Phase 2
- Fulvestrant Phase 2
- Gedatolisib Phase 2
- Indocyanine green Phase 3
- Ipilimumab Phase 1